SynthesisClinical lung cancer2015

Should Tyrosine Kinase Inhibitors Be Considered for Advanced Non-Small-Cell Lung Cancer Patients With Wild Type EGFR? Two Systematic Reviews and Meta-Analyses of Randomized Trials.

Claire L Vale et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.